More Respimat data from Boehringer
Boehringer Ingelheim on Tuesday touted results from the Phase III CanoTinA asthma trial, which showed that adding tiotropium Respimat to maintenance asthma therapy in kids ages 6-11 significantly improves lung function compared to placebo. The results were presented Tuesday at the European Respiratory Society International Congress 2016 in London. This comes 1 day after results from another clinical trial showed the company’s drug-device Stiolto Respimat aids patients with chronic obstructive pulmonary disease walk for longer periods of time without experiencing shortness breath. The Can...
Source: Mass Device - September 8, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Boehringer Ingelheim Pharmaceuticals Source Type: news

Tiotropium Respimat < sup > ® < /sup > improved lung function in children with asthma
Tiotropium Respimat® improved lung function in children with asthma (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 7, 2016 Category: Research Source Type: news

MassDevice.com +5 | The top 5 medtech stories for September 6, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Boehringer Ingelheim touts Stiolto Respimat data Boehringer Ingelheim yesterday touted results from a Phase III trial showing that its Stiolto Respimat, a drug-device combination helps people with chronic obstructive pulmonary ...
Source: Mass Device - September 6, 2016 Category: Medical Equipment Authors: MassDevice Tags: Blog Plus 5 Source Type: news

Boehringer Ingelheim touts Stiolto Respimat data
Boehringer Ingelheim yesterday touted results from a Phase III trial showing that its Stiolto Respimat, a drug-device combination helps people with chronic obstructive pulmonary disease walk for longer periods of time while relieving some shortness of breath. When participants with moderate to severe COPD took Stiolto Respimat, a combination of tiotropium bromide and olodaterol, along with exercise, their exercise capacity increased by 45.8% compared to those receiving a placebo. The Physacto trial is a part of the Tovito Phase III clinical trial, investigating the efficacy of Respimat as a maintenance therapy for COPD. &l...
Source: Mass Device - September 6, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Respiratory Boehringer Ingelheim Pharmaceuticals Source Type: news

Tiotropium RESPIMAT ® Improved Lung Function with Safety Comparable to Placebo in Children with Asthma
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - September 6, 2016 Category: Research Source Type: news

New Data: STIOLTO(R) RESPIMAT(R) (tiotropium bromide+olodaterol) Inhalation Spray Significantly Improved Exercise Capacity in People with COPD
RIDGEFIELD, Conn., Sept. 5, 2016 -- (Healthcare Sales & Marketing Network) -- Boehringer Ingelheim today announced the first results from the Phase IIIb/IV PHYSACTO trial that showed STIOLTO RESPIMAT, combined with exercise training, helps people with COP... Biopharmaceuticals, Devices, Drug Delivery Boehringer Ingelheim, STIOLTO RESPIMAT, tiotropium, olodaterol, COPD (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 5, 2016 Category: Pharmaceuticals Source Type: news

New Data: STIOLTO ® RESPIMAT® (tiotropium bromide+olodaterol) Inhalation Spray Significantly Improved Exercise Capacity in People with COPD
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - September 5, 2016 Category: Research Source Type: news

SPIRIVA < sup > ® < /sup > RESPIMAT < sup > ® < /sup > Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents
SPIRIVA ® RESPIMAT ® Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

New Analyses: Adding SPIRIVA < sup > ® < /sup > Respimat < sup > ® < /sup > Effective for Uncontrolled Asthma
New Analyses: Adding SPIRIVA ® Respimat ® Effective for Uncontrolled Asthma (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

ERS Congress 2013 New Phase III data presented for first time demonstrate: tiotropium* Respimat < sup > ® < /sup > significantly improves lung function and provides sustained bronchodilation in asthma patients who remain symptomatic despite ICS † treatment
ERS Congress 2013 New Phase III data presented for first time demonstrate: tiotropium* Respimat ® significantly improves lung function and provides sustained bronchodilation in asthma patients who remain symptomatic despite ICS † treatment (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

" AAAAI 2014 ASTHMA: New Phase III data show tiotropium* Respimat < sup > ® < /sup > effective across asthma severities "
" AAAAI 2014 ASTHMA: New Phase III data show tiotropium* Respimat ® effective across asthma severities " (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Landmark TIOSPIRTM trial reinforces importance of SPIRIVA < sup > ® < /sup > in both available formulations as the world's leading maintenance therapy for chronic obstructive pulmonary disease (COPD)
Landmark TIOSPIRTM trial reinforces importance of SPIRIVA ® in both available formulations as the world's leading maintenance therapy for chronic obstructive pulmonary disease (COPD) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Phase III results: tiotropium* Respimat < sup > ® < /sup > is effective in symptomatic asthma patients irrespective of their allergic status
Phase III results: tiotropium* Respimat ® is effective in symptomatic asthma patients irrespective of their allergic status (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Phase III results: tiotropium* Respimat < sup > ® < /sup > effective in symptomatic asthma patients despite at least ICS †/LABA‡ independent of their age, allergic status, smoking status and bronchodilator response
Phase III results: tiotropium* Respimat ® effective in symptomatic asthma patients despite at least ICS †/LABA‡ independent of their age, allergic status, smoking status and bronchodilator response (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Boehringer Ingelheim submits applications in Europe to extend the indication for the use of tiotropium Respimat < sup > ® < /sup > to the treatment of asthma in adults aged 18 years and over
Boehringer Ingelheim submits applications in Europe to extend the indication for the use of tiotropium Respimat ® to the treatment of asthma in adults aged 18 years and over (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Additional results from post-hoc analysis underline effectiveness of SPIRIVA < sup > ® < /sup >
Additional results from post-hoc analysis underline effectiveness of SPIRIVA ® (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

ATS 2014 COPD: First Phase III data show lung function benefits of tiotropium + olodaterol fixed-dose combination go beyond tiotropium (Spiriva < sup > ® < /sup > ) alone
ATS 2014 COPD: First Phase III data show lung function benefits of tiotropium + olodaterol fixed-dose combination go beyond tiotropium (Spiriva ® ) alone (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

New large-scale study to investigate effect of tiotropium + olodaterol Respimat < sup > ® < /sup > on exacerbations in COPD
New large-scale study to investigate effect of tiotropium + olodaterol Respimat ® on exacerbations in COPD (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

" European Respiratory Society International Congress 2014 TONADO < sup > ™ < /sup > - further lung function and quality of life benefits with tiotropium + olodaterol Respimat < sup > ® < /sup > FDC* in COPD "
" European Respiratory Society International Congress 2014 TONADO ™ - further lung function and quality of life benefits with tiotropium + olodaterol Respimat ® FDC* in COPD " (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Asthma: new indication for Spiriva < sup > ® < /sup > (tiotropium) Respimat < sup > ® < /sup > * in the EU may offer millions of adults a significant advance in asthma care
Asthma: new indication for Spiriva ® (tiotropium) Respimat ® * in the EU may offer millions of adults a significant advance in asthma care (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

New data show benefit of tiotropium/olodaterol Respimat < sup > ® < /sup > from the start of COPD maintenance therapy
New data show benefit of tiotropium/olodaterol Respimat ® from the start of COPD maintenance therapy (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Asthma: U.S. FDA approves new indication for SPIRIVA < sup > ® < /sup > Respimat < sup > ® < /sup >
Asthma: U.S. FDA approves new indication for SPIRIVA ® Respimat ® (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Asthma: Boehringer Ingelheim announces U.S. FDA filing acceptance of NDA for Spiriva < sup > ® < /sup > Respimat < sup > ® < /sup > in asthma
Asthma: Boehringer Ingelheim announces U.S. FDA filing acceptance of NDA for Spiriva ® Respimat ® in asthma (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

​Pulmatrix shares climb as generic Spiriva hits goals in early-stage trial
An inhalable drug for chronic obstructive pulmonary disease, or COPD, being developed by Lexington biotech Pulmatrix and drug giant Mylan, met its goals in an early-stage trial, potentially clearing the way to be marketed in Europe. The news boosted the stock price of the small local biotech by 10 percent this morning to $2.45 a share, giving the company a market value of $36 million. Pulmatrix (Nasdaq: PULM) has a method of delivering drugs using a dry powder it calls iSPERSE which it says is… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 19, 2016 Category: Pharmaceuticals Authors: Don Seiffert Source Type: news

Stiolto Respimat (tiotropium bromide and olodaterol) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 24, 2016 Category: Drugs & Pharmacology Source Type: news

Boehringer Ingelheim and HealthPrize Partner to Launch New Support Program for People Treating COPD With SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray
People living with chronic obstructive pulmonary disease (COPD) can earn rewards for tracking medication use and learning more about COPD (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 8, 2016 Category: Research Source Type: news

Tiotropium inhalation spray effective for asthma regardless of allergic status
LOS ANGELES – Once-daily tiotropium bromide inhalation spray as long-term, add-on maintenance therapy in patients with poorly controlled symptomatic asthma is similarly effective in both allergic and... (Source: Pediatric News)
Source: Pediatric News - May 1, 2016 Category: Journals (General) Source Type: news

Tiotropium inhalation spray effective for asthma regardless of allergic status
LOS ANGELES – Once-daily tiotropium bromide inhalation spray as long-term, add-on maintenance therapy in patients with poorly controlled symptomatic asthma is similarly effective in both allergic and... (Source: Family Practice News)
Source: Family Practice News - May 1, 2016 Category: Primary Care Source Type: news

Lancet Publication: New Analysis Demonstrates Only Small Minority of Severe/Very Severe COPD Patients May Benefit from Adding ICS to SPIRIVA® HANDIHALER® (tiotropium bromide inhalation powder) + LABA Therapy
• New post-hoc analysis shows routine eosinophil blood test could help identify the small minority   of severe/very severe patients who may benefit from addition of ICS* • Only 20 percent of patients in WISDOM† study benefited from addition of ICS on top of SPIRIVA®   HANDIHALER®‡ and a LABA§ with regards to exacerbation risk reduction • The data analysis, published in Lancet Respiratory Medicine, adds to current debate about appropriate   selection of patients for ICS treatment in chronic obstructive pulmonary disease (COPD) (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - April 8, 2016 Category: Research Source Type: news

FDA Approves Supplemental New Drug Application (sNDA) for Boehringer Ingelheim’s STIOLTO® RESPIMAT® (tiotropium bromide and olodaterol) Inhalation Spray for COPD Health-Related Quality of Life
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - March 29, 2016 Category: Research Source Type: news

New Analyses: Adding SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray Effective for Uncontrolled Asthma – Regardless of Allergy Subtype
• SPIRIVA® RESPIMAT® shown effective in the broad range of asthma patients studied who continued   to experience symptoms despite taking other asthma maintenance therapies • New analyses show improved lung function* and asthma symptom control and reduced asthma   exacerbations† for patients with allergic asthma (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - March 7, 2016 Category: Research Source Type: news

Newly Published Head-to-Head Data Show STIOLTO™ RESPIMAT® (tiotropium bromide and olodaterol) Improved Lung Function Across Range of Measures
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - February 9, 2016 Category: Research Source Type: news

SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents
SPIRIVA RESPIMAT is the first new class of inhaled medicine approved in over 10 years for the treatment of asthmaSPIRIVA RESPIMAT works differently than other medicines to help people with asthma breathe better (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - February 3, 2016 Category: Research Source Type: news

AAFP NRN Study Sheds Light on Asthma Treatment in Black Adults
A recent study examined treatment options for black adults with asthma, finding no difference between adding tiotropium or a long-acting beta agonist to inhaled corticosteroids. (Source: AAFP News)
Source: AAFP News - February 2, 2016 Category: Primary Care Source Type: news

Tiotropium/olodaterol in COPD: Disadvantages in some patients, advantages in others
(Institute for Quality and Efficiency in Health Care) For most patients, the fixed-dose combination has neither advantages nor disadvantages. More flare-ups occur in higher severity grades. Women with rare flare-ups have advantages. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 20, 2015 Category: Global & Universal Source Type: news

Asthma: No Clear Winners in Combination Treatment in Blacks Asthma: No Clear Winners in Combination Treatment in Blacks
A randomized trial showed no benefit to long-acting beta-agonists over tiotropium in combination with inhaled corticosteroid for improving outcomes in black adults with asthma. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 18, 2015 Category: Consumer Health News Tags: Internal Medicine News Source Type: news

Asthma: LABA + Steroids Not a Winning Combo for Blacks
(MedPage Today) -- Tiotropium is just as good as steroid add-on and perhaps safer (Source: MedPage Today Pulmonary)
Source: MedPage Today Pulmonary - October 27, 2015 Category: Respiratory Medicine Source Type: news

Spiriva Respimat (Tiotropium Bromide Inhalation Spray) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 2, 2015 Category: Drugs & Pharmacology Source Type: news

Spiriva Respimat (Tiotropium) Gets Asthma Indication in USSpiriva Respimat (Tiotropium) Gets Asthma Indication in US
The FDA approved a once-daily dose, delivered in two puffs, for long-term maintenance treatment of asthma in people aged 12 years and older. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 16, 2015 Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news

Tiotropium (Spiriva Respimat) Gets Asthma Indication in USTiotropium (Spiriva Respimat) Gets Asthma Indication in US
The FDA approved a once-daily dose, delivered in two puffs, for long-term maintenance treatment of asthma in people aged 12 years and older. FDA Approvals (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 16, 2015 Category: Allergy & Immunology Tags: Pulmonary Medicine News Alert Source Type: news

Cardiac Safety of Tiotropium in Patients With Cardiac EventsCardiac Safety of Tiotropium in Patients With Cardiac Events
How safe is the HandiHaler in COPD patients who've had a recent cardiac event? Respiratory Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 1, 2015 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news

Olodaterol/tiotropium improves QOL in patients with COPD
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - August 1, 2015 Category: Drugs & Pharmacology Source Type: news

Stiolto Respimat (tiotropium bromide and olodaterol) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 13, 2015 Category: Drugs & Pharmacology Source Type: news

Boehringer’s Spiolto Respimat COPD therapy approved in European countries
Boehringer Ingelheim Spiolto Respimat (tiotropium / olodaterol) once-daily maintenance treatment has received regulatory authority approvals in first European countries, to relieve symptoms in adult patients with chronic obstructive pulmonary disease… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 3, 2015 Category: Pharmaceuticals Source Type: news

tiotropium bromide and olodaterol (Stiolto Respimat)
Title: tiotropium bromide and olodaterol (Stiolto Respimat)Category: MedicationsCreated: 7/2/2015 12:00:00 AMLast Editorial Review: 7/2/2015 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - July 2, 2015 Category: Respiratory Medicine Source Type: news

tiotropium bromide and olodaterol (Stiolto Respimat)
Title: tiotropium bromide and olodaterol (Stiolto Respimat)Category: MedicationsCreated: 7/2/2015 12:00:00 AMLast Editorial Review: 7/2/2015 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - July 2, 2015 Category: Drugs & Pharmacology Source Type: news

Stiolto Respimat (tiotropium bromide and olodaterol) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 5, 2015 Category: Drugs & Pharmacology Source Type: news

Boehringer’s once-daily Stiolto Respimat receives FDA approval for COPD
Boehringer Ingelheim has received approval from the US Food and Drug Administration (FDA) for its once-daily Stiolto Respimat (tiotropium bromide and olodaterol) inhalation spray. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 28, 2015 Category: Pharmaceuticals Source Type: news

FDA Approves Stiolto Respimat for COPDFDA Approves Stiolto Respimat for COPD
The oral inhalation spray combines fast-acting olodaterol and tiotropium, which appear separately in other Respimat-style products. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 26, 2015 Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news

Poorly Controlled Asthma: Is This Drug the Answer?Poorly Controlled Asthma: Is This Drug the Answer?
Although not yet approved in the United States, tiotropium studies are beginning to show that it may have a useful role in patients whose asthma remains poorly controlled despite combination therapy. Medscape Pulmonary Medicine (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - May 19, 2015 Category: Allergy & Immunology Tags: Pulmonary Medicine Viewpoint Source Type: news